Results 141 to 150 of about 117,631 (302)

RNA‐binding protein RBMS1: A new target for cancer diagnosis and treatment

Precision Medical Sciences, EarlyView.
This schematic illustrates the diverse regulatory roles of RNA‐binding motif single‐stranded interacting protein 1 (RBMS1) across multiple human cancers. In breast cancer, RBMS1 stabilizes B4GALT1 mRNA to promote PD‐L1 glycosylation, modulating tumor immune escape and immunotherapy efficacy.
Xingda Run, Shiwei Jiang, Kun Xu, Yu Fan, Yanwen Chen, Ziao Liu, Zengli Miao, Wei Tian   +7 more
wiley   +1 more source

Combining radiotherapy with CAR‐T cell therapy for solid tumors: Challenges, mechanisms, and future directions

Precision Radiation Oncology, EarlyView.
Radiotherapy enhances CAR‐Tcell therapy by increasing antigenicity, improving trafficking, and reshaping the tumor microenvironment. Despite its dual effects, including potential immune suppression, understanding these mechanisms enables the development of strategies to maximize synergy in solid tumors.
Leran Qiu, Xingyu Zhou, Jiao Xue, Xiaokang Zhang, Songbing Qin   +4 more
wiley   +1 more source

Advances in mucosal injury mechanisms in radiation‐induced esophagitis associated with thoracic radiotherapy

Precision Radiation Oncology, EarlyView.
There is no specific therapeutic drug regimen for radiation esophagitis. In previous studies, radiation esophagitis was considered a self‐limiting disease; however, current clinical approaches are limited to symptomatic treatment, which yields unsatisfactory therapeutic outcomes.
Hao Zhang, Liangxue Luo, Chaofen Zhao, Bibo Wu, Jing Zhang, Lingfeng Liu, Bing Lu, Shengfa Su   +7 more
wiley   +1 more source

Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 583-595, March 2025.
ABSTRACT Prior pharmacokinetic (PK) analysis revealed that increased alpha‐1‐acid glycoprotein (AAG) levels are associated with decreased imatinib unbound fraction in coronavirus disease 2019 (COVID‐19) patients. This study aimed to investigate the PK of total and unbound concentrations of imatinib and the metabolite N‐desmethyl imatinib in ...
Medhat M. Said, Job R. Schippers, Leila Atmowihardjo, Yingxue Li, Mick S. van der Plas, Harm J. Bogaard, Lieuwe D. J. Bos, Ron A. A. Mathôt, Jurjan Aman, Eleonora L. Swart, Imke H. Bartelink   +10 more
wiley   +1 more source

Microglial Activation Under Hypoxic Conditions in Early Alzheimer's Disease: Can Natural SIRT1 Activators Be Therapeutic Allies in the Inflammation–Energy Axis?

Phytotherapy Research, EarlyView.
ABSTRACT Alzheimer's disease (AD) is a progressive neurodegenerative condition characterized by a preclinical stage that typically lasts for decades. Early on during this time, microglia react to pathological changes and become protective and even transiently delay neurodegeneration.
Sara Merlo, Cristiana Lucia Rita Lipari, Aurora Patti, Maria Angela Sortino   +3 more
wiley   +1 more source

The role of Janus kinase signaling in graft-versus-host disease and graft versus leukemia [PDF]

, 2018
Choi, Jaebok, DiPersio, John F, Schroeder, Mark A, Staser, Karl   +3 more
core   +2 more sources

Flavonoids in Nasal Therapeutics: Biological Activities, Delivery Challenges, and Formulation Strategies–A Systematic Review

Phytotherapy Research, EarlyView.
Overview of the therapeutic potential of flavonoids in nasal delivery systems, highlighting their benefits to the human nasal cavity, and applications in the treatment of respiratory and brain‐related diseases. ABSTRACT Flavonoids represent a significant group of secondary metabolites.
Jeniffer Viviana Ramirez Hernández, Sara Elis Bianchi, Flávia Nathiely Silveira Fachel, Elizandra Braganhol, Sheila Porto de Matos, Valquíria Linck Bassani   +5 more
wiley   +1 more source

Mesenchymal stromal cell therapy for rheumatoid arthritis: Long‐term efficacy, safety, and mechanistic insights

Rheumatology &Autoimmunity, EarlyView.
Graphical abstract summarizing the multifactorial pathogenesis of rheumatoid arthritis (RA) and the therapeutic potential of mesenchymal stromal cell (MSC) therapy. MSCs provide promising benefits through their immunomodulatory properties, low immunogenicity, ability to promote tissue repair, and multi‐lineage differentiation, presenting a potential ...
Yingjia Chen, Ruiyu Gao, Xing Guo, Genhong Yao, Xiaojun Tang, Yile E. Liu, Lingyun Sun   +6 more
wiley   +1 more source

Impact of biological/targeted versus conventional synthetic disease‐modifying antirheumatic drugs on patient‐reported outcomes in rheumatoid arthritis

Rheumatology &Autoimmunity, EarlyView.
Patient‐reported outcomes (PROs) were compared among rheumatoid arthritis patients who maintained low disease activity or remission for at least 6 months based on the disease‐modifying antirheumatic drug (DMARD)administered. Even with comparable disease activity, methotrexate (MTX) group, biological/targeted synthetic DMARDs (b/tsDMARDs), particularly ...
Masafumi Sugiyama, Saki Okuda‐Tsuchimoto, Takashi tsuchimoto, Koji Kinoshita, Itaru Matsumura   +4 more
wiley   +1 more source

Type I interferon overactivation in sera of patients with anti‐MDA5‐positive dermatomyositis‐associated interstitial lung disease

Rheumatology &Autoimmunity, EarlyView.
Sera from patients with anti‐MDA5‐positive dermatomyositis‐associated interstitial lung disease (ILD) exhibit significantly higher type I interferon (IFN‐I) bioactivity and interferon‐stimulated gene‐inducing activity compared to anti‐ARS‐positive ILD and healthy controls.
Shohei Nakamura, Yasuhiro Katsumata, Yuko Okamoto, Masayoshi Harigai   +3 more
wiley   +1 more source